Dyne Therapeutics Inc

Dyne Therapeutics is a clinical-stage biotechnology company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. The company develops therapeutics targeting muscle and the central nervous system to address the root cause of disease, leveraging its proprietary FORCE platform. Dyne's pipeline includes clinical programs for Duchenne muscular dystrophy (DMD) with z-rostudirsen (exon 51 skipping, BLA under FDA Priority Review) and four additional DMD candidates targeting exons 53, 45, 44, and 55; z-basivarsen for myotonic dystrophy type 1 (DM1) in registrational and Phase 3 trials; and DYNE-302 for facioscapulohumeral muscular dystrophy (FSHD) with a recently cleared IND. The company also has preclinical programs in Pompe disease and multiple DMD mutations. Dyne trades on Nasdaq under the ticker DYN and is transitioning toward becoming a commercial-stage organization with a potential first product launch anticipated in Q1 2027. Updated Jul 29, 2026